Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. (Q40429761)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

title

Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

author name string

F Volpin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

J Casaos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

J Sesen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

A Mangraviti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

J Choi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

J Frikeche

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

T Lott

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

R Felder

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

S J Scotland

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

T S K Eisinger-Mathason

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

H Brem

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

B Tyler

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

N Skuli

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

language of work or name

English

0 references

publication date

12 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

number of pages

11

1 reference

inferred from page(s)

published in

Oncogene

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

issue

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

page(s)

3037-3047

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27941882%20AND%20SRC:MED&resulttype=core&format=json

Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action

29 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Advances in hepatitis C therapy: What is the current state - what come's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Ribavirin: Past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Modulation of cancer pathways by inhibitors of guanylate metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Further evidence that ribavirin interacts with eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Expression of eukaryotic initiation factor 4E in astrocytic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Does the ribosome translate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Use of the Ki67 promoter to label cell cycle entry in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Sindbis virus mutants resistant to mycophenolic acid and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Drug repurposing in oncology--patient and health systems opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Targeting translation in acute myeloid leukemia: a new paradigm for therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Sox2 is translationally activated by eukaryotic initiation factor 4E in human glioma-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G(1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Anti-glioma action of aloe emodin: the role of ERK inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Glioma cell proliferation controlled by ERK activity-dependent surface expression of PDGFRA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

EZH2 is essential for glioblastoma cancer stem cell maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Snail depletes the tumorigenic potential of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Brain distribution of ribavirin after intranasal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Effective ribavirin concentration in mice brain using cyclodextrin as a drug carrier: evaluation in a measles encephalitis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Viramidine demonstrates better safety than ribavirin in monkeys but not rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

The genotoxic and cytotoxic effects of ribavirin in rat bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Translation initiation factor eIF4E is a target for tumor cell radiosensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Int6/eIF3e is essential for proliferation and survival of human glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Non-virally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Ribavirin as a tri-targeted antitumor repositioned drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Efficacy of ribavirin against malignant glioma cell lines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.457

Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.

31 March 2020

1 reference

12 December 2020

Snail plays an oncogenic role in glioblastoma by promoting epithelial mesenchymal transition

1 reference

12 December 2020

Clinical review of ribavirin.

1 reference

12 December 2020

Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation.

1 reference

12 December 2020